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1. Abstract 33 
Among pediatric patients, preterm neonates and newborns are the most vulnerable subpopulation. 34 
Rapid developmental changes of physiological factors affecting the pharmacokinetics of drug 35 
substances in newborns require extreme care in dose and dose regimen decisions. These 36 
decisions could be supported by in silico methods such as physiologically-based 37 
pharmacokinetic (PBPK) modeling. In a comprehensive literature search, the physiological 38 
information of preterm neonates that is required to establish a PBPK model has been summarized 39 
and implemented into the database of a generic PBPK software. Physiological parameters 40 
include the organ weights and blood flow rates, tissue composition, as well as ontogeny 41 
information about metabolic and elimination processes in the liver and kidney. The aim of this 42 
work is to evaluate the model’s accuracy in predicting the pharmacokinetics following 43 
intravenous administration of two model drugs with distinct physicochemical properties and 44 
elimination pathways based on therapeutic drug monitoring (TDM) data. To this end, PBPK 45 
models of amikacin and paracetamol have been set up to predict their plasma levels in preterm 46 
neonates. Predicted plasma concentration-time profiles were compared to experimentally 47 
obtained TDM data. For both drugs, plasma concentration-time profiles following single and 48 
multiple dosing were appropriately predicted for a large range gestational and postnatal ages. In 49 
summary, PBPK simulations in preterm neonates appear feasible and might become a useful tool 50 
in the future to support dosing decisions in this special patient population. 51 
Keywords: physiology, preterm, newborn, maturation, pharmacokinetic, amikacin, paracetamol 52 
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2. Introduction 55 
 56 
Preterm neonates are the most vulnerable subpopulation in pediatrics. Even in Western European 57 
countries, the United States of America and Japan preterm birth is still associated with a high risk 58 
of morbidity and mortality. Pharmacological interventions in this patient group are frequent but 59 
impeded by the fact that the majority of drugs used have not been properly tested and licensed for 60 
pediatric application. It has been estimated that up to 93% of neonates in intensive care units 61 
(ICU) receive at least one unlicensed medicine during their stay in an ICU [1-3] or a medication 62 
in a way not covered by the drug label. This unlicensed or off-label use of medicines in children 63 
is associated with an increased risk of serious adverse drug events and fatalities [1-3]. Legislation 64 
providing voluntary or mandatory mechanism to conduct clinical studies in pediatric patients is in 65 
place in Europe and the US [4, 5]. Although pediatric regulation resulted in general in an increase 66 
in clinical trials involving children and label extensions towards use in pediatrics [5], the number 67 
of drugs studied in newborns, and in particular in preterm neonates, has remained very small [6]. 68 
Because the pharmacokinetics of drugs usually significantly differ between preterm and term 69 
neonates, infants and adults, dose and dosing regimen decisions can be extremely difficult for 70 
pediatricians and are usually derived from adult regimens relying on heuristics such as linear or 71 
allometric extrapolations based on body weight only. Thus, children and in particular preterm 72 
neonates undergoing pharmacotherapy could greatly benefit from tools and techniques that 73 
support the pediatrician to find a safe and efficient dose or dosing scheme tailored to the 74 
individual patient [7, 8].  75 
Due to the ethical concerns and difficulties associated with clinical trials in children and 76 
particularly in term and preterm neonates, additional techniques and tools for supporting dose and 77 
dosing regimen decisions in pediatrics are highly desired. One of the most promising tools in this 78 
context is physiologically-based pharmacokinetic (PBPK) modeling. This technique has become 79 
more and more accepted within the pharmaceutical industry and several successful applications 80 
have already been published [9-13]. With the help of PBPK modeling, the absorption, 81 
distribution, metabolism and excretion (ADME) of drugs in children of various age groups can be 82 
predicted based on models established in adults. Such predictions can help to make PK studies in 83 
children safer, easier and more reliable.  84 
The aim of this study is to develop a generic PBPK model for preterm neonates. In the first step, 85 
the parameters relevant for PBPK modeling that include anatomical and physiological 86 
information such as organ weights, blood flow rates as well as maturation information of hepatic 87 
enzymes and kidney functions are collected from the literature and implemented into a database. 88 
Neonates aged from 40 weeks down to preterms with a gestational age (GA) of 24 weeks were 89 
targeted in our literature search. Although rare survivors have been documented as early as 22 90 
weeks of gestational age GA, 24 weeks of GA is generally referred to be the limit of viability at 91 
which the newborn has a 50% chance of survival [14]. This typically represents the cutoff point 92 
when pediatricians will use intensive medical intervention to save the preterm’s life because 93 
survival rates are extremely low for babies born earlier. In the second step, the predictivity of the 94 
model is assessed based on therapeutic drug monitoring data (TDM) of two drugs, amikacin and 95 
paracetamol, in preterm neonates of different GA and postnatal age (PNA).  With regard to the 96 
administration route, this study focuses on intravenous (IV) drug delivery, which is the main 97 
route of drug administration in preterm neonates.  98 
 99 
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3. PBPK Model development 101 
The preterm model will be implemented in a previously developed generic software platform for 102 
PBPK modeling (PK-Sim®, Bayer Technology Services GmbH, Leverkusen, Germany). Up to 103 
now, PK-Sim® facilitates PK simulations for a variety of laboratory animals (mouse, rat, dog, 104 
minipig, and monkey) as well as humans down to term neonates. The model contains 18 organs 105 
and tissues, namely arterial and venous blood, adipose tissue, brain, bone, gonads, heart, kidneys, 106 
large intestine, liver, lung, muscle, portal vein, pancreas, skin, small intestine, spleen, stomach. 107 
The organs are further divided into four sub-compartments. These are the plasma, the red blood 108 
cells (which together build the vascular space), the interstitial space and the cellular space. 109 
Compound-specific model parameters such as organ/plasma partition coefficients, permeability-110 
coefficients etc. are calculated from physicochemical properties of the compound and from the 111 
composition of tissues in terms of water, protein and the different types of lipids [15]. The 112 
generic structure of the PBPK model implemented in PK-Sim® is illustrated in Fig. 1. 113 
 114 
3.1. Anatomical data 115 
To extend the physiological database containing the relevant parameters for PBPK modeling 116 
towards preterm neonates, a comprehensive literature search was performed. The collected 117 
physiological parameters including their developmental changes are summarized in Table 1. 118 
Relevant parameters considered in the model are body weight and height, the volumes and blood 119 
flow rates of the various organs, the tissue composition and the physiology of the gastro-120 
intestinal tract (besides the fact that oral drug administration is only exceptionally performed in 121 
preterm neonates [16]). For a closer look to these data see Table 1 and Figure 2.  122 
Standard weights for normal healthy fetuses and thereby weight and size distributions were 123 
obtained from intrauterine growth charts (Fig. 2) [17-25]. In the first few days of postnatal life, 124 
preterm (as well as term) neonates typically undergo a short phase of weight loss. This weight 125 
loss is equivalent to a “dip” in the postnatal growth curve for body weight as evident in Figure 2. 126 
The depth and time of occurrence of the weight curves minimum depends on body weight at birth. 127 
The absolute and relative loss in body weight is smallest for the very light and, accordingly, the 128 
very young preterms. A preterm neonate with a birth weight of 550 g, for example, loses 129 
approximately 5 g (or 1% of its body weight), whereas a baby born near term with a birth weight 130 
of 2500 g might lose approximately 150 g (or 6% of its body weight) during the first days of 131 
postnatal life [26, 27]. Sex differences were not considered in case of preterm neonates with the 132 
exception of the volume of the gonads [28, 29]. For the most important organs, age dependent 133 
weights or volumes and their growth rates could be retrieved (Table 1 and Fig. 3A). Apparently, 134 
organ growth is not solely related to the body weight, but shows a very complex pattern. In 135 
particular the relative contribution of fat and muscle tissue to the overall body weight of a 136 
preterm changes during fetal and early postnatal development. Muscle, fat, bone and brain 137 
represent the largest organs in preterm neonates (Table 1). Several organs show linear growth 138 
(Fig. 3A), whereas the adipose tissue grows exponentially during fetal life. These changes affect 139 
the distribution volume of drugs and are, thus, important to be considered in drug dosing 140 
decisions.  141 
While direct measurements of organ weights were available for brain, lung, heart, liver, spleen, 142 
pancreas and kidney, only indirect measurements were available for skin and stomach. For these 143 
organs, weight-age relationships could be established on the basis of the reported surface area and 144 
the thickness. It has to be kept in mind, however, that the majority of reported data was obtained 145 
post mortem during autopsies, which could have influenced the measurements, especially in case 146 
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of the skeleton mass, where the tissue was reported to be macerated [30]. Furthermore, all organ 147 
weights summarized in this article refer to exsanguinated organs and require a correction for their 148 
blood content, as already described by Edginton et al. in order to obtain the total organ weight in 149 
vivo [10].  150 
Developmental changes in organ blood flow rates were only poorly described in the literature, 151 
with only measurements of cardiac output [31, 32] and renal blood flow rates [33] being reported. 152 
For the PBPK model it was assumed that the organ-specific percentage contributions to total 153 
cardiac output in a preterm newborn are identical to those in term neonates [10], an assumption 154 
supported by the data presented for renal blood flow by Visser et al [33]. Developmental blood 155 
flow changes are depicted in Figure 3B. Similar to the organ specific blood flow rates, the 156 
postnatal changes in the organ composition are only poorly described in the literature and had to 157 
be extrapolated from term newborns [10].  158 
Physiological information about the gastro-intestinal tract is also available to a sufficient extent, 159 
at least with respect to tissue weights. Physiological data that is only relevant for the simulation 160 
of oral administration such as luminal pH, geometric dimensions and transit times, were included 161 
mainly for the reason of completeness. Their relevance for the PBPK model is limited because 162 
oral drug administration is only performed in exceptional cases [16]. 163 
Because immature function of the eliminating organs in preterm neonates can contribute 164 
considerably to the age-dependence and inter-individual variability of pharmacokinetics, prior 165 
knowledge about enzyme activities in the liver and maturity of kidneys during fetal life and in the 166 
early postnatal period is essential for a predictive PBPK preterm model. Thus, information about 167 
liver and kidney maturation were also compiled in dependence of the GA and PNA as 168 
additionally described below. The total age range in this report covers the weeks 24 to 40 of GA 169 
(second and third trimester fetuses) and the first two years of postnatal life.  170 
 171 
 172 
3.2.  Model for maturation of glomerular filtration 173 
For the simulation of the age-dependence of glomerular filtration rate (GFR), the maturation 174 
model presented by Rhodin et al. [34] was modified to make use of the more detailed 175 
physiological knowledge, in particular the kidney volume of an individual at a given age. Rhodin 176 
et al. described the GFR of preterm neonates by a sigmoid maturation function of postmenstrual 177 
age (PMA) in combination with an allometric size factor with exponent 0.75 relative to an adult 178 
individual with standard weight of 70 kg [34]: 179 
                                 180 
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Here, TM50 denotes the maturation half time and GFRmat represents the mature value for GFR in 183 
a healthy adult individual weighing 70 kg. The Hill exponent determines the steepness of the 184 
sigmoidal maturation curve. As a measure of the neonates weight (WEIGHT), the best model was 185 
obtained by the authors when normal fat mass (NFM) was used rather than total body weight 186 
(BW) [34].  187 
In the context of a whole-body PBPK model, the influence of size can be directly displayed by 188 
the (a priori known) volume of the kidney. We therefore replaced the allometric size factor by a 189 
linear scaling factor of the kidney volume at a given PMA normalized to the kidney volume of an 190 
adult individual with a standard weight of 70 kg (440 mL  [35]). In addition, a small fractional 191 
offset in the GFR (fGFRpremat) was introduced that corrects for a tendency to slightly 192 
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underestimate the observed median GFR values in preterm infants below approximately 32 193 
weeks of gestation:  194 
 195 
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 197 
Eq. (3) was used in this study to re-fit the age-dependent GFR data provided in the study by 198 
Rhodin et al. [34]. The parameter identification was performed using MATLAB’s 199 
FMINSEARCH routine yielding the following values (mean ± s.d.): Hill = 15.0 ± 0.3, TM50 = 200 
44.4 ± 1.0 weeks, fGFRpremat = 0.256 (fixed), GFRmat = 117 ± 27 ml/min. The resulting 201 
description of GFR vs. age is shown in Fig. 4 in comparison to the median and 90% confidence 202 
interval of the data collected by Rhodin et al. [34] for a virtual population of preterm neonates (A) 203 
and over the first 20 years of life (B). For validation purposes, the results of the modified Rhodin-204 
model were also compared to a second set of GFR maturation data in preterm neonates 205 
previously presented by Vieux et al. [36] which showed overall correspondence. 206 
 207 
 208 
3.3. Model for liver maturation 209 
The liver is the main organ involved in drug metabolism. Besides the liver size, metabolic phase I 210 
or II reactions depend on the activity and amount of drug metabolizing enzymes (DME). Infants 211 
have different capacities to metabolize drugs, so that some substances might produce either lower 212 
or higher plasma concentrations than expected. The differences in enzyme activity can alter the 213 
production of intermediate metabolites. DME ontogeny has been recently reviewed by Hines et al. 214 
[37]. A summary of the data collected by the author is given in Table 2. 215 
Apparently, there are three different groups of DME. Enzymes belonging to the first group are 216 
expressed at their highest level during the first trimester. These enzymes remain on this high level 217 
of expression or decrease during gestation until they get silenced with birth. Cytochrome P450 218 
(CYP) 3A7, flavin monooxygenase (FMO) 1, sulfotransferase (SULT) 1E1 and perhaps 219 
glutathione S-transferase (GST) 3 belong to this group. Enzymes revealing the expression 220 
patterns of the second category, e.g. CYP3A5, SULT1A1 and UDP-glucuronosyltransferase 221 
(UGT) 1A3, show relatively constant levels throughout life. Enzymes that are not or weakly 222 
expressed during gestation and that show an increase of expression during late gestation or 223 
postnatally belong to the third group of enzymes. The majority of DMEs obeys this expression 224 
pattern and for example includes alcohol dehydrogenase (ADH), CYP2C9, CYP3A4, and 225 
UGT2B17. The increase in enzyme expression is most often observed within the first or second 226 
postnatal year [37]. Up to now, the knowledge about the ontogeny of enzymes still increases and 227 
gives further insight into drug metabolism in developing infants.  228 
In addition to drug metabolism via enzymes, drugs can be excreted via bile. Development from 229 
progenitor cells into a differentiated organ, in which bile secretion can be observed, occurs at 230 
around 12 weeks of GA [38]. Therefore, the biliary excretion in the model is expected to be the 231 
same as in term neonates [39].  232 
The preterm model was extended by integrating the information about hepatic enzyme ontogeny 233 
in fetuses and preterm neonates as referred in Table 2. The enzyme ontogeny necessary for the 234 
prediction of paracetamol PK is described in more detail below. Elimination of paracetamol 235 
occurs primarily by hepatic metabolism (95% of total body clearance). Three enzymes are mainly 236 
responsible for paracetamol hepatic clearance. Metabolization occurs via CYP2E1, via SULT1A1 237 
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and via UGT1A6. Compared to adults, enzyme activity in preterm neonates and fetuses is 238 
reduced to 0-10% for CYP2E1 as this enzyme was not detected in fetuses, but arises postnatally. 239 
SULT1A1 is reduced during all fetal stages to 62% and UGT1A6 is reduced to 1-10% of adult 240 
enzyme activity [40-42]. All three enzymes thereby belong to the third group of enzymes 241 
reviewed in Table 2, that is, their enzyme activities increase postnatally.  242 
 243 
 244 
3.4. Model evaluation: Amikacin 245 
Amikacin is an aminoglycoside antibiotic used for short-term treatment of serious infections (due 246 
to multidrug resistant Gram negative bacteria such as Pseudomonas species [43]). Since amikacin 247 
is excreted primarily by GFR [44, 45] the clearance of amikacin should be predictable solely 248 
based on knowledge about kidney maturation and, accordingly, developmental changes in GFR. 249 
For the evaluation of the newly established PBPK model for preterm neonates, the 250 
pharmacokinetics of amikacin were predicted based on an amikacin model previously established 251 
for adults [46]. The drug related parameters described in Table 3 were kept as defined in the adult 252 
model, whereas age-dependent parameters including anatomy and physiology as well as the 253 
developmental changes in drug clearance were adapted using the parameter database described in 254 
Table 1 and Fig. 2 and 3.  255 
Simulated data was compared to experimentally obtained amikacin levels [47]. In the 256 
experimental study, 701 preterm and term neonates (GA 24 to 41 weeks) were given amikacin 257 
according to a GA-based dosing chart during their first days of life. This chart was developed in 258 
2002 by Langhendries et al. [48]. Recommended doses were: GA < 28 weeks: 20 mg/kg/42 hours, 259 
GA 28-30 weeks: 20 mg/kg/36 hours, GA 31-33 weeks: 18.5 mg/kg/30 hours, GA 34-37 weeks: 260 
17 mg/kg/24 hours, GA > 37 weeks: 15.5 mg/kg/24 hours. Amikacin was given as an IV infusion 261 
over 20 minutes. In general, blood samples were collected by arterial line or venous puncture just 262 
before (trough value) and 40 minutes after completion of the second IV dose of amikacin [44, 45].  263 
We simulated virtual preterm populations consisting of 500 male and 500 female preterm 264 
subjects for each PMA. The GA ranges from 24 to 40 weeks of gestation with postnatal growing 265 
steps of one day up to 30 days of PNA. Thus, a total of 480 populations for the span of 16 weeks 266 
of GA times 30 days of PNA, each including 1000 individuals, were simulated. The dynamic 267 
growth occurring during repeated drug administration as described earlier is also considered in 268 
these populations. From these populations, ten virtual individuals with the same PMA at birth and 269 
minimal differences in body weight when compared to the patients in the in vivo studies were 270 
selected for comparison. For those, the percentage % of predicted data points deviating by a 271 
factor of two, three and ten were calculated according to  272 
 273 
%x = nfactx/ ntotal       (3) 274 
 275 
The index x indicates the factor of deviation (x = 2, 3, or 10). Here, nfactx denotes the number of 276 
datapoints that fall within the interval [1/x..x] and ntotal is the total number of datapoints. 277 
 278 
3.5. Model evaluation: Paracetamol 279 
Paracetamol (acetaminophen) is used as an antipyretic and analgesic agent for preterm neonates 280 
having painful treatments, or as additional treatment for neonates receiving opioids [49]. In adults, 281 
the metabolization via CYP2E1 accounts for about 10%, the metabolism mediated by SULT1A1 282 
accounts for approximately 30-35% and the metabolism via UGT1A6 accounts for 45-55% of the 283 
total body clearance, respectively [50].Overall, the age-dependence of paracetamol PK is 284 
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governed by hepatic maturation and ontogeny of enzymes involved in its metabolism (see section 285 
3.3). Paracetamol is frequently administered intravenously in the form of its prodrug 286 
propacetamol, which is rapidly hydrolyzed to paracetamol by plasma esterases [42]. After IV 287 
administration of 2000 mg of propacetamol, the prodrug is hydrolyzed to 1000 mg of 288 
paracetamol [3].  289 
Starting point for the paracetamol model for preterms was a previously published paracetamol 290 
model for adults and children [51]. The physicochemical properties of paracetamol are 291 
summarized in Table 3. For the evaluation of the model predictions, data obtained in 108 292 
neonates were available [41, 42], from which measurements of 106 neonates could be used (two 293 
patients were excluded from this analysis because they were older than 40 weeks of GA). In the 294 
in vivo study, preterm neonates with a PMA of 7 to 43 weeks of gestation and a PNA of one to 76 295 
days were given either single (n=39) or multiple doses (n=69) of 20 mg/kg propacetamol as an 296 
infusion over 15 minutes. With respect to age, the virtual populations were the same as for the 297 
amikacin study. That is, virtual populations of 500 male and 500 female preterm subjects for each 298 
PMA, ranging from 24 to 40 weeks of gestation with growing steps of one day were used. As 299 
already described for amikacin, ten virtual individuals with the same PMA at birth and minimal 300 
differences in body weight when compared to the patients of the in vivo paracetamol study were 301 
selected and the mean values from these populations were taken for the individual simulations. 302 
For model analysis calculations see section 3.4. 303 
 304 
4. Model evaluation results 305 
 306 
4.1.  Amikacin 307 
Fig. 5 shows the correlation between the predicted and observed amikacin plasma concentrations 308 
in preterm neonates (dots), with the solid line indicating the line of identity (solid line). The data 309 
are classified by color with respect to PMA ranging from very young preterm infants with a PMA 310 
of 24 weeks (blue) to term born neonates with a PMA of 40 weeks (dark red). The results indicate 311 
that the predicted plasma concentrations depend on PMA. In particular peak plasma 312 
concentrations of predicted plasma amikacin levels rise with smaller gestational age. This leads 313 
to the separation of the predicted peak plasma concentrations of amikacin according to 314 
gestational ages, as evident from Fig. 5. This separation disappears in the case of the trough 315 
concentrations due to the high interindividual variability in renal clearance. This indicates a 316 
slightly higher variation in GFR than found in the predicted data, while the opposite was evident 317 
in the case of the trough values. 318 
Calculations of the deviations between predicted values and TDM data reveal that 78.4% of all 319 
amikacin predictions have a deviation factor of two or smaller. More than 90% of the predictions 320 
fall within a deviation factor of three and 98.5% within a deviation factor of ten. Only a slight 321 
bias towards lower predicted concentrations might be observed in the higher postmenstrual ages 322 
(38-42 weeks of PMA). Most of the underpredicted plasma concentrations can be explained by 323 
renal pathologies documented by extremely high serum creatinine levels (SCr), as shown in Fig. 324 
5B. Here, the ratios of predicted/observed plasma concentrations of amikacin vs. experimentally 325 
obtained plasma creatinine values are shown. This figure reveals a trend of decreasing plasma 326 
creatinine values with rising PMA. Additionally, the plasma creatinine rises with a larger bias 327 
towards lower predictions. Most preterms with exceptionally high creatinine values are of higher 328 
PMA. 329 
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Amikacin pharmacokinetics for the multiple dosing of amikacin are shown in Fig. 6 for three 330 
exemplary preterms. The individuals were selected for different gestational ages, multiple dosing 331 
and availability of TDM data points. Individuals shown in Fig. 6 are 27, 33 and 36 weeks of 332 
PMA. As obvious, after a treatment phase of one week there was a washout period of one week, 333 
followed by a second and, if necessary, a third therapy cycle. Overall, the simulated plasma 334 
concentration-time curves match the experimentally observed TDM data quite accurately 335 
regardless of the gestational or postnatal age.  336 
 337 
4.2.  Paracetamol 338 
In Fig. 7, the predictions of paracetamol plasma concentrations are plotted against plasma 339 
concentrations obtained from TDM data. Again, increasing postmenstrual ages are illustrated by 340 
the color of the data points. In case of paracetamol, no tendency towards higher plasma levels 341 
with decreasing gestational or PNA could be observed. Overall, the model predicted the 342 
paracetamol plasma concentrations of preterm neonates quite accurately: 92.1% of all predicted 343 
paracetamol plasma levels were within 2-fold of the observed data, 98.8% of predicted data 344 
points fall within a deviation factor of three and 99.6% have a maximum deviation of 10 from the 345 
TDM data. No biases, e.g. related to age, were detected. Additionally, individual plasma 346 
concentration-time curves of paracetamol are shown (Fig. 8) for three exemplary individuals aged 347 
31, 36 and 40 weeks of GA. The simulated plasma concentration-time curves almost perfectly 348 
match the data observed in the clinic. 349 
 350 
5. Discussion 351 
 352 
Neonates born prematurely often require intensive care treatment including pharmacotherapeutic 353 
interventions. In most of the cases, drugs that are administered in the neonatal intensive care units 354 
have neither been licensed nor properly studied in this patient group. Unfortunately, preterm 355 
responses to drugs differ from those of adults, children and term babies because of 356 
pharmacokinetic and pharmacodynamic differences. In the postnatal episode, developmental 357 
changes occur at different rates both between individual preterms and when compared to term 358 
neonates. For these reasons, the safe and efficient drug treatment of preterm neonates still 359 
remains an enormous challenge for the pediatrician. In pharmaceutical development, researchers 360 
responsible for the planning of clinical studies in children (often including preterm neonates) 361 
have to propose the first dose in children on the basis of clinical data obtained in older patients 362 
starting from adults through adolescents down to toddlers and newborn individuals. Both in 363 
clinical practice and drug development, a knowledge-based approach considering all available 364 
information about physicochemistry of the drug and the state and rate of development of the 365 
preterm neonate patients as a function of GA and PNA is highly desirable.  366 
In this study we investigated if whole-body PBPK modeling can potentially serve this need. The 367 
PBPK technology has been widely applied to various aspects of drug research and development 368 
[52] as well as in environmental risk assessment [53], and its acceptance in the industry and in 369 
regulatory agencies – in particular with respect to pediatric applications – is increasing. While 370 
several successful application examples in adult humans and children down to term neonates [10, 371 
54] have been published in the literature, preterm neonates have so far not been a subject of 372 
physiologically-based simulations. A major hurdle was the availability of the relevant age-373 
dependent anatomical and physiological information that is required to parameterize a PBPK 374 
model. This hurdle was overcome by a comprehensive literature search (Fig. 2-3, Table 1-2). The 375 
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required data could be gathered and implemented into the database of PK-Sim® allowing a – 376 
technically simple –  down-scaling of pre-existing human adult PBPK models. 377 
To evaluate the predictivity of the preterm PBPK model, two model drugs were selected based on 378 
the (i) the availability of clinical data in preterm neonates and (ii) differences in drug distribution 379 
and elimination behavior. While amikacin is a renally cleared antibiotic with relatively low 380 
distribution volume (approximately 0.25 – 0.50 L/kg in adults [55]), the analgesic drug 381 
paracetamol mainly undergoes hepatic metabolization and distributes to a greater extent to 382 
peripheral compartments (distribution volume in adults around 1 L/kg [56]). 383 
 384 
The comparison of predicted plasma levels with TDM data obtained in the clinic for both drugs 385 
indicated that the physiologically-based model is indeed able to accurately predict the 386 
pharmacokinetics in preterm neonates. In case of amikacin, 78.4% of the predictions are within a 387 
factor of two or smaller of the TDM data, in case of paracetamol, the accuracy was even better 388 
with 92.1% of all predicted data points being within a two-fold range of the observed data. Inter-389 
individual variability in the GFR (as was evident from reported serum creatinine values) was 390 
identified as the main cause of the under-predicted amikacin plasma concentrations. This 391 
observation implicates that the GFR, which was included based on a modified version of the GFR 392 
model previously established by Rhodin et al. [34], is not appropriate for some of the preterm 393 
patients. This is not surprising because only healthy neonates were considered by Rhodin et al., 394 
while the TDM studies for amikacin (as well as paracetamol) included hospitalized preterms that 395 
were treated for diseases with at least the mentioned drugs. The exceptionally high plasma 396 
creatinine values of near term infants included in the amikacin study indicated a possible renal 397 
damage and, as a result, a lower GFR has to be expected. The trend towards rising plasma 398 
creatinine values for preterm babies with lower PMA can be explained by the fact that these 399 
babies were of lower PNA. As such, the plasma levels are affected by the maternal creatinine 400 
values. At birth, infants have a plasma creatinine value of maternal circulation which decreases 401 
with postnatal age.  402 
These very good predictions of the paracetamol TDM data implicate an appropriate description of 403 
the underlying physiological and anatomical data, a correct estimation of the volume of 404 
distribution and hepatic metabolism of the drug in preterm patients.  405 
In conclusion, the presented PBPK model is a very promising first step towards a tool that 406 
predicts the pharmacokinetic behavior of a drug in preterm neonates. The physiological database 407 
contains the relevant data for virtual individuals down to a gestational age of 24 weeks. In the 408 
future, the tool might be applied to support dosing decisions and improve the treatment options 409 
for the very young ones and, thus, provide helpful information for designers of clinical studies 410 
involving preterm neonates as well as caretakers in neonatal units. 411 
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9. Figures 631 
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 633 
Fig. (1). Structure of the whole simulation model of PK-Sim® with all included 634 
organs. 635 
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636 
Fig. (2).  Postnatal growth curves for preterm infants pooled in different weight 637 
classes up to two years (black solid lines) compared to term born infants matched to 638 
the growth charts of the “Centers for Disease Control and Prevention” (CDC) (grey-639 
shaded area). Postnatal changes in body weight [kg] are shown. 640 
 641 
 642 
 643 
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 645 
 646 
 647 
 648 
 649 
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A) 650 
  651 
B) 652 
 653 
Fig. (3). Physiological data obtained from literature review: A) Median organ weights for 654 
different organs in preterm infants from 24 to 40 weeks of as percentage of body weight. 655 
The median body weight per GA is shown. B) Estimation of blood flow for different organs 656 
in preterm infants from 24 to 40 weeks of GA in ml/min/kg tissue weight.  657 
 658 
 659 
  19
 660 
Fig. (4). Representation of changes in GFR (in ml/min) with gestational age (in weeks) in 661 
comparison to the data presented by Rhodin et al. In both plots the original Rhodin model 662 
is indicated as grey line, while our adjusted model is represented by black lines. (A) Zoom 663 
in to the first weeks of GA (B) Development of GFR over the first 20 years of life.  664 
 665 
 666 
 667 
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(A) 680 
 681 
(B)  682 
 683 
Fig. (5). (A) Comparison of plasma amikacin concentrations of population 684 
simulations with amikacin TDM data [44, 45] from preterm neonates at different 685 
PMA’s (B) Changes of creatinine values [mg/dl] with the ratio of predicted vs. 686 
observed plasma concentrations (shown in 3A) with PMA.  687 
  21
 688 
Fig. (6). Comparison of predicted plasma concentration time curves (solid line) with 689 
patient data (x) for multiple doses of amikacin in three representative patients with 690 
ages of (A) 27 weeks GA, PNA 1 day, (B) 33 weeks GA, PNA 1 day,  (C) 36 weeks 691 
GA, PNA 1 day at the day of administration.  692 
 693 
 694 
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(A)      712 
 713 
(B) 714 
 715 
Fig. (7). Comparison of plasma paracetamol concentrations from population 716 
simulations with paracetamol TDM data [44, 45] from preterm neonates at (A) 717 
different PMA’s and (B) different PNA’s. 718 
 719 
 720 
  23
 721 
Fig. (8). Comparison of predicted plasma concentration time curves (solid line) with 722 
patient data (x) for multiple doses of paracetamol in three different patients at the 723 
ages of (A) 31 weeks GA, PNA 2 days, (B) 36 weeks GA, PNA 17 days GA,  (C) 40 724 
weeks GA, PNA 4 days at the day of administration. 725 
 726 
10. Tables 727 
 728 
Table 1: Source, data type and publication date of data about organ weights and 729 
organ growth in preterm neonates included in the PBPK model. 730 
Data Set Year Used in the model for 
following Organs  
Methods Population 
Archie et al [57] 2006 Brain, Heart, Kidney, Liver, 
Lung, Pancreas, Spleen 
Autopsy Fetal and Neonatal 
Ben-Haroush et al 
[58] 
2005 Stomach Sonographic examination Fetuses 16-42 weeks of 
GA 
Koo et al [59] 2000 Adipose tissue Dual energy X-ray 
absorptiometry (DXA) 
Neonates, 27-42 weeks of 
GA 
Malas et al [28]  2001 Gonads (Testis) Autopsy Fetuses, 12-40 weeks of 
  24
GA 
Malas et al [60] 2003 Jejunum, Ileum Autopsy Fetuses 10-40 weeks of 
GA 
Malas et al [61] 2004 Colon Autopsy Fetuses 10-40 weeks of 
GA 
Meban et al [62]  1983 Skin Autopsy 11-42 weeks of GA 
Modi et al [63]  1990 Muscle Urinary creatinine Neonates, 25-34 weeks of 
GA 
Petersen et al [64]  1995 Skin High frequency 
ultrasound 
Newborn infants 
Roe [65] 1933 Skin Autopsy Fetuses 
Shah et al [66]  1988 Small, Large Intestine Autopsy Fetuses, 20-40 weeks of 
GA 
Smith [67] 2002 Blood volume Posttransfusional HCT 
and GA 
Preterm infants 21-35 weeks 
of GA 
Struijs et al [68]  2009 Intestinal lengths Autopsy Infants 25 weeks of GA to 5 
years 
Sulak et al [29]  2004 Gonads (ovary) Autopsy Fetuses 9-40 weeks of GA 
Touloukian et al 
[69]  
1983 Intestinal lengths Autopsy 19-40 weeks of GA 
Trotter et al [30] 1969 Skeleton Autopsy Fetuses 
 731 
Table 2:  Ontogeny of drug metabolizing enzyme activities in % of adult enzymatic 732 
activity for fetuses and preterm infants (based on Hines [70]). 733 
 Early 
gestation 
10-20 
weeks of 
GA 
Mid gestation 21-30 
weeks of GA 
Late 
gestation 
31-40 
weeks of 
GA 
postnatal Ref. 
Oxidative enzymes      
Alcoholdehydrogenase      
ADH  31%*  45% Smith et al. [71] 
Cytochrome P450 system      
  25
CYP1A1  low or no expression*   Shao et al. [72]/ 
Hines et al. [37] 
CYP1A2  5%*  10% Alcorn et al. 
[73] 
CYP1B1  undetectable*  Bieche et al. 
[74] 
CYP2A6  low or no expression*   Gu et al. [75] 
CYP2A13  undetectable*   Bieche et al. 
[74] 
CYP2B6  50%   Croom et al. 
[76] 
CYP2C 
 
0%*  3% Alcorn et al. 
[73] 
CYP2C9 0% 4-5% 10% 25% Koukouritaki et 
al. [77] 
CYP2C18 
 
undetectable*  Bieche et al. 
[74] 
CYP2C19 0% 1% 10-20% 50% Koukouritaki et 
al. [77] 
CYP2D6 5% 5% 6% 9% Treluyer et al. 
[78]/ Alcorn et 
al. [73] 
CYP2E1 0% 0% 0% 10% Vieira et al. 
[79] 
CYP3A4 
 3%  13% 
Alcorn et al. 
[73] 
CYP3A5  is present, no change as 
function of age* 
  Stevens et al. 
[80] 
CYP3A7  500%*  130% Alcorn et al. 
[73]/ Stevens et 
al. [80] 
FMO system      
FMO1 100% 50% 25% 0% Koukouritaki et 
al. [81] 
FMO3 0% 0% 0% 50% 
Koukouritaki et 
al. [81] 
Conjugation enzymes      
Epoxide hydrolase      
EPHX1 6% 10% 32% 50% Omiecinski et 
al. [82] 
Glutathione S-transferases      
GSTM (GST1)  22%*  93% Strange et al. 
[83] 
GSTA (GST2)  25%*  62% Strange et al. 
[83] 
GSTP (GST3)  5300%*  2100% Strange et al. 
[83] 
Sulfotransferases      
SULT1A1  62%*   Stanley et al.  
[84] 
SULT1A3  340%*   Stanley et al. 
[84] 
SULT1E1  106%*   Stanley et al. 
[84] 
SULT2A1  26%*   Stanley et al. 
[84] 
  26
UDP 
glucuronosyltransferases 
     
UGT1A3  30%*   de Wildt et al. 
[85] 
UGT1A6  1-10%*   de Wildt et al. 
[85] 
UGT2B7  10-20%*   de Wildt et al. 
[85] 
UGT2B17  8%*  11% de Wildt et al. 
[85] 
 * = values refer to all fetal stages 734 
Table 3: Physicochemical properties of the two model drugs. 735 
Parameter Amikacin Paracetamol 
Lipophilicity (log MA) -0.48 0.78 
Molecular weight [g/mol] 585.6 151.16 
Plasma fraction unbound fu) 1.0 0.82 
 736 
